Answers are grounded in this paper and cite their sources.
INTRODUCTION: Faricimab is a bispecific antibody that enables greater disease control and extended durability compared with vascular endothelial growth factor (VEGF) inhibition alone in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). This study aimed to evaluate its effectiveness, durability, and economic and social burden in Italian clinical practice. METHODS: FARIT was a retrospective, observational, multicenter cohort study across four Italian sites. Adult patients with nAMD or DME who initiated faricimab from February 2023 and had ≥ 6 months of follow-up were included. Clinical outcomes, treatment patterns, and patient-reported data were collected through chart review and electronic surveys. RESULTS: A total of 87 eyes (68 with nAMD, 19 with DME) were followed for a median of 14 months. Among them, 33 eyes (24 with nAMD, 9 with DME) were anti-VEGF naïve. At 1 year, 95.4% and 100% of naïve eyes with nAMD and DME, respectively, reached a dosing interval of every 12 weeks (Q12W) or longer; 63.6% and 100% received the treatment every 16 weeks (Q16W). Among switch eyes, 92.4% (nAMD) and 71.5% (DME) reached ≥ Q12W, with 35.9% and 42.9%, respectively, on Q16W dosing. After a full loading phase, the median number of injections administered during the post-loading follow-up period (12 months for nAMD, 10 months for DME) was three for nAMD and two for DME. The interval extensions were driven by visual acuity stabilization/improvement and fluid resolution. Patients and caregivers reported high satisfaction and reduced burden, with fewer injections and better visual outcomes contributing most to improved quality of life. Economic analysis showed a 12-month direct cost (excluding the drug cost) of 1223.8 €/patient from the healthcare system perspective. CONCLUSIONS: Faricimab provided effective disease control and extended treatment intervals in treatment-naïve and previously treated eyes with nAMD and DME, showing a fast anatomical response and reduced injection burden.
No takes yet. Share an insight, caveat, or question.
Lupidi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: